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Abstract
The Internet has enabled profound changes in the way science is performed, especially in scientific communications.
Among the most important of these changes is the possibility of new models for pre-publication review, ranging from the
current, relatively strict peer-review model, to entirely unreviewed, instant self-publication. Different models may affect
scientific progress by altering both the quality and quantity of papers available to the research community. To test how
models affect the community, I used a multi-agent simulation of treatment selection and outcome in a patient population
to examine how various levels of pre-publication review might affect the rate of scientific progress. I identified a ‘‘sweet
spot’’ between the points of very limited and very strict requirements for pre-publication review. The model also produced a
u-shaped curve where very limited review requirement was slightly superior to a moderate level of requirement, but not as
large as the aforementioned sweet spot. This unexpected phenomenon appears to result from the community taking longer
to discover the correct treatment with more strict pre-publication review. In the parameter regimens I explored, both
completely unreviewed and very strictly reviewed scientific communication seems likely to hinder scientific progress. Much
more investigation is warranted. Multi-agent simulations can help to shed light on complex questions of scientific
communication and exhibit interesting, unexpected behaviors.
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Introduction
Modern science is a highly collaborative, community practice.
Scientists often collaborate directly, and the scientific literature
supports building upon previous work over time. New electronic
publishing technologies, such as e-journals, forums, and blogs, offer
the enticing possibility of highly efficient instant publication, rather
than authors having to go through the cumbersome processes of
classic peer review and long publication cycles. In the extreme,
scientists may put their lab notebooks or straight-off-the-instrument
data online. Of course, unreviewed publication is a venerable
tradition both inclassic and modern science; scientists often publishin
books, editorials, and other venues that are not peer reviewed; some
h a v ee v e nr u nt h e i ro w np r e s s e s ,l i k eB e n j a m i nF r a n k l i nd i d .B u tt h e
ease and speed with which one can publish on the Web, combined
with the critical role that Web searchhastakenasthe first resource for
nearly all scientific scholarship, raises new possibilities and the
potential for new problems. Nielsen [1] eloquently describes the
possibilities: ‘‘The Internet offers us the first major opportunity [to
create] a conversational commons for the rapid collaborative
development of ideas.’’ On the other hand, the Internet poses
problems with information quality control. Shrager et al. [2] suggest
that reducing pre-publication review requirements may lead to a
decrease in the average quality of the information stream; high-
quality information will be less clearly marked, and information may
be quickly posted and therefore less stable due to revisions. With the
vast amount of information available, scientists could act based on
unreliable information. Although some rapidly-published results are
available for post-publication review, readers often miss these types of
reviews. Moreover, as the pace of information distribution in the
community speeds up, a vicious cycle may result that pushes
researchers to act faster to ensure they publish first, potentially
reducing their capacity to check their own results. A Web-based
review process must be carefully designed to allow for easy filtering of
publications based upon their review type and quality.
Ominous as this scenario may sound, it is not entirely clear that
these changes are for the worse. The rapidity with which results
are posted and shot down may balance out a decrease in the
quality of published results. Thus even if the signal-to-noise ratio of
published results is reduced, the search among alternative
hypotheses could take place so much faster that this balances
out the time wasted by the community in following up published
results that turn out to be invalid.
Whether, and under what model, pre-publication review should
take place is no mere academic question; scientists encounter this
struggle daily. Po ¨schl [3] recently observed that ‘‘shorter articles
and an increasing number of publications have resulted in the
scientific information market being flooded by journal articles,
preprints and proceedings with little or no quality control.’’
Moreover, unreviewed (or lightly reviewed) material is rapidly
leaking into the supposedly validated scientific literature without
any indication of the level of review it has received. For example,
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expert group of influenza researchers, but in the interest of
timeliness, does not undergo in-depth peer review.’’ Yet the
abstracts from this journal appear in PubMed–a widely accepted
source for validated biomedical publication–with no indication
they have not undergone in-depth peer review. By contrast, arXiv
[5] provides quality control through two levels of review,
endorsement and moderation, and will not certify a paper until
it has appeared in a peer-reviewed journal.
With the current state of the review process, and new publication
paradigms rapidly upon us, now is the time to question the impact
that a flood of lightly reviewed scientific publications could have on
scientific progress. For example, the first volume of the newly minted
Journal of Participatory Medicine (JPM) [6] launched online in October
2009, featured an essay wherein Richard W. Smith [7], former editor
oftheBritishMedicalJournal, encouraged the readershipofJPMto help
design a new alternative to traditional peer review: ‘‘[We] don’t yet
have a clearly articulated alternative to peer review, but this is your
chance to ‘join the revolution’ and together with the editors devise a
better system for this journal.’’ Smith asks his readers to consider a
model under which newdata isput online immediately, with reviewer
and editor comments available after online publication. But again,
our modern Web experience suggests that post-publication com-
mentary of this sort often goes largely unnoticed. Indeed, Google’s
Page Rank algorithm ranks documents primarily based upon the
number of citations, pushing papers, with more citations higher in
rank even if the citations are not complementary.
Although Web-based publication has not yet resulted in the
chaos envisioned by Shrager, et al., we are rapidly headed for a
world of increasingly lightly reviewed, post-reviewed, or unre-
viewed scientific publications. In his exhortation, Smith asks the
readers to contribute their thoughts based on evidence. There are
various sorts of evidence that might bear on this problem. In the
present paper, I employ a multi-agent, computational simulation
to explore what impact self-publication and lightly reviewed, post-
reviewed, or unreviewed publication might have on the progress of
science. Multi-agent simulations have been used to good effect in a
wide variety of domains [8], but have rarely been used to model
the scientific community. Payette [9] developed a multi-agent
simulation based upon the hypothesis that scientists earn the
respect of their peers through sharing ideas with their collaborators
and competitors. In this model, scientists ‘‘propagate their ideas
[and] acquire credit, i.e., the consideration of their peers, with
whom they are both competing and collaborating.’’ Payette’s
simulated scientists operate in a social network with their students
and collaborators while writing peer-reviewed articles that allow
them to share their ideas with the whole community. Each idea is
assigned a real-value of ‘empirical adequacy’, although the
scientists do not have direct access to this value and must
approximate it using tests. When ideas are transmitted from one
scientist to another, noise can be introduced into the transmission,
and the efficiency of the system is measured by how close the
subjective ratings assigned by the agents to ideas come to the real,
objective correctness of the idea.
My model employs a similar multi-agent approach to the
question of whether pre-publication review accelerates or hinders
the progress of science. I simulate the health of a community with
a population of 1000 persons and realistic probabilities of getting a
progressive, fatal disease, such as cancer. In this model, patients
with cancer are treated with the best available published
treatment, and observe the population after 100 years. Like
Payette’s model, the present model contains ubiquitous and
inherent measurement noise; it is impossible for any agent to
directly observe the true state of health of themselves or of any
other agent. This will come into play in trying to understand how
the predictions and observed results arise. The main variable I
explore here is the stringency of the requirements for publication,
modeled here as the number of sequentially observed improve-
ments in a particular patient’s health status; that is, approximately:
replications required to publish. I call this ‘HMSDCALE’ and
abbreviate is as: ‘@N’, where N is the minimum number of
sequentially observed improvements required to publish. The
present experiments vary HMSDCALE in the range of @1 (very
weak replication requirements) through @12 (very strict replica-
tion requirements). I predict that both extremes on the scale will be
inferior to mid-range values, and the population size will decrease
over the course of one-hundred years; however, the explanation
for this downward trend is different at each end of the scale. At the
weak end (near @1), nonsense observations will rapidly fill the
literature, misleading the community to adopt improper treat-
ments, whereas at the strict end (near @12) almost nothing will be
published because measurement noise makes it almost impossible
to achieve the required number of sequentially observed
improvements in the patient’s health. In this latter scenario,
treatment selection has no basis in published evidence and is
therefore effectively random. Both of these cases should have
adverse consequences for the overall health of the population.
More details of the model appear in the Materials and Methods
section below.
Results
Figure 1 depicts the number of patients that remain alive at the
end of 100 years of simulation across a range of HMSDCALE
values from @1 through @12. These data are accumulated over
250 replicated runs with different random seeds. The error bars
represent standard errors (s.e.). Overall, this result is highly
significant (F(11,2988)=69.43, p,=0.00), but further analysis is
required in order to confirm or refute the theory put forward
above.
Figure 1. Populations after 100 years of simulation across
increasing values of HMSDCALE (@1-12). Standard error (s.e.) bars
are over 250 replications with different random seeds. (The s.e. bars are
so small as to be nearly invisible at high values of HMSDCALE.)
doi:10.1371/journal.pone.0010782.g001
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HMSDCALE values. This happens because measurement error
makes it very unlikely to observe high numbers of sequential
declines, even in a patient whose health is improving monoton-
ically. As a result, very few effective treatments are published in
this upper range of HMSDCALE. There is a fairly smooth decline
from @5 through @8, reaching a minimum of about 300 people
alive after 100 years. Not surprisingly, this is about the same result
obtained if random treatments are given. In post-hoc ANOVA
analysis (by Tukey HSD), there are no significant differences
between @9-@12, but @7-@12 all show highly significant
differences (p,.001) from the other values (@1-@6). The
HMSDCALE at @7 is nearly significantly different from each
value in @9 to @12 (9v7,=0.08, 10v7,=0.08, 11v7,=0.07,
12v7,=0.08). Of the remaining post-hoc comparisons, the only
significantly different ones were as follows: 5v1,=0.001,
4v2,=0.03, 5v2,=0.00, 5v3,=0.00, and 6v5,0.01.
Notice that comparing @1 to @5, the final population increases
significantly (p,=0.001) followed by the decline described above.
An increase from @1 through some medium point is roughly what
was expected. This supports the hypothesis that lightly reviewed
publication is inefficient, and some moderate level of publication
stringency is superior to either very weak or very strong levels. Five
simulated years of observed, monotonic improvement in disease
state is approximately the ‘‘sweet spot’’ for pre-publication
replication requirements in this particular simulation regimen.
Interestingly, the values between @1 and @5 decrease
somewhat. Although @1 is not significantly different from @2–
4, there is a difference between @2 and both @4 and @5, and a
difference greater than the standard error between both @2 and
@3 compared to @5, yielding post-hocs of 4v2,=0.03,
5v2,=0.00, and 5v3,=0.00. This u-shaped result was not
expected, so I explored it in more detail. A closer look at the
standard errors suggests the data in this range is essentially
bimodal; either the population discovers the right treatment,
publishes the results fairly rapidly, and essentially everyone
survives; or they never discover it, resulting in approximately the
same lower population as in the higher values on the scale. What is
changing in the @1–5 range is the number of the 250 runs that
land in each of these regimens.
One can more clearly observe this bimodality by splitting the
data shown in Figure 1 into the high-end and low-end of the scale.
To show this more easily, I have split the data at a remaining
population of 800. Table 1 gives the total number of runs of the
250 where the population after 100 years was greater than or
equal to 800 as well as the associated means and standard errors
(s.e). This division significantly reduces the s.e. for almost all of the
data, from a s.e. around 25 in the @2–5 range down to s.e. in the
low single digits. This supports the hypothesis of strong bimodality
in the data, and can be seen by looking at any of the dynamics in
the @1-@6 range. Notice that the number of people remaining
after 100 years is around 170 for all of the ,800 cases in @2–5,
which is around the level of the null treatment; that is, all patients
are always treated with a drug that has no effect. This suggests that
once someone randomly discovers a good treatment, everyone still
alive at that point is saved. If this happens early in the simulation,
almost everyone is saved. But unless and until the correct
treatment is discovered and published, everyone is being treated
randomly, and with mostly poor treatments. The HMSDCALE
parameter simply pushes the point in time when this discovery
takes place to a later date, making it harder to discover a good
treatment but also improving the performance of the treatment
once discovered. At low HMSDCALE values, incorrect treatments
are published and have little utility, whereas, as the HMSDCALE
rises up to a point around @5 or @6, the quality of the published
treatments is improved. However, these discoveries come later in
the run. After about @6, publication starts to be so difficult that
eventually nothing is published at all and treatments are essentially
random. And indeed, the level reached, about 300, is about the
same as random treatment. Note that random treatment is slightly
superior to null treatment as the variation inherent in the random
approach means the treatments may be either more or less
effective than the null. The parameters of the present model lean
slightly toward more good than poor treatments. The combination
of these phenomena creates the observed complex dynamics.
Discussion
Although limited in scope and applicability, these results suggest
that different levels of stringency in peer review may accelerate or
hinder scientific progress. Too strict of a review requirement
(represented here by the HMSDCALE parameter) can prevent
sharing of valid treatments, but too weak of a requirement drowns
good results in a sea of bad treatments. Moreover, unexpected,
non-linear complexities appear between the point of too little
Table 1. Statistics from 250 runs split between a final population of .=800 v.,800 after 100 years.
@ combined Mean combined se n.=800 .=800 mean .=800 se n,800 ,800 mean ,800 se
1 578.82 19.53 86 966.79 4.86 164 375.37 11.98
2 528.19 26.16 109 997.33 0.56 141 165.52 1.86
3 547.34 26.21 115 995.00 0.68 135 166.01 2.10
4 611.16 25.94 135 988.50 1.03 115 168.20 2.26
5 682.69 23.72 162 957.69 2.37 88 176.45 2.88
6 586.73 20.74 105 898.78 5.18 145 360.76 20.58
7 387.00 12.34 18 884.61 13.12 232 348.39 9.28
8 322.69 4.34 1 803.00 0.00 249 320.76 3.90
9 0 250 310.32 1.50
10 0 250 310.63 0.92
11 0 250 309.24 0.92
12 0 250 310.72 0.93
doi:10.1371/journal.pone.0010782.t001
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improvements (@5).
These results certainly have not answered the specific question
of exactly how much pre-publication review is too much or too
little. For example, it is unlikely that doctors should wait five years
for the improvement of a cancer patient before publishing.
(Coincidentally, cancer-free for five years is exactly what is
considered a ‘‘cure’’ in oncology.) However, I have shown that a
relatively simple model can suggest general principles and reveal
interesting, complex phenomena that invite further analysis. In
this way, multi-agent models offer a new instrument for
investigation of the complex social structures that are modern
science.
Materials and Methods
Supporting file Text S1 contains the complete, self-contained
Common Lisp code for the model, along with the parameter
values that produced the results presented here.
Agents, that is, patients, doctors, or patient–doctor units,
operate in an environment of a single disease (e.g., cancer) and
numerous potential treatments. A population of patients (here
1000) stochastically becomes ill, for example, at a rate of 0.01 of
the population per year. When the disease is initially diagnosed in
a given person, it has a real-valued level (0.1), and progresses each
year by a fixed factor (1.26) until it reaches a death threshold (0.5).
At this point the individual is removed from the population.
Patients visit the doctor once each year and either continue with or
change their current treatment. The model is usually run for 100
simulated years, and I conduct 250 replication runs with different
random seeds. The available drugs used to treat the disease take
on a range of multiplicative effectiveness, with an effectiveness of
1.0 having no effect (i.e., a null treatment). Values smaller than 1.0
denote beneficial effects (i.e., reducing the level of the disease), and
those greater than 1.0 denote undesired side effects (i.e.,
accelerating towards the death threshold). For example, if a
person is diagnosed at 0.1 and is treated for three years with a null
drug (effectiveness=1.0) and a disease progression factor of 1.2, he
or she will have a disease level of ,0.173 in the third year. If he or
she then begins treatment with a drug that has a treatment
effectiveness of 0.8, his or her next disease level will be
0.17361.260.8=0.166, then 0.159, etc., and this patient will
eventually be ‘‘cured’’ if he or she remains on this drug; that is, the
disease level will approach, although never quite reach, 0.0.
In the present model, every person employs the same decision
algorithm. When initially diagnosed, the patient gets the best drug
reported in the literature at the time. This method is described
below. If the disease has not apparently improved by the patient’s
annual visit to the doctor, that is, the measured disease level has
not reduced, this patient is again treated with the current best drug
in the literature, which will almost certainly have changed since
the patient’s last visit. Note that on each visit to the doctor the
patient’s actual state of health can only be measured with a
standard deviation of 2.0, so that the actual state of the patient’s
health is not directly observable, similar to Payette’s model.
Agents in the present model interact with one another via
publication. At each annual treatment, either the patient or his or
her doctor may publish the result in the collective literature, which
is a simple, chronological stack. Results are only published after
the patient has a number of sequential improvements while taking
the same drug, as determined by the HMSDCALE parameter.
Recall that patient improvement inherently contains error, so that
an error on a single measurement could cause a misinterpretation
of the patient’s state. I use the notation ‘‘@N’’ to indicate an
HMSDCALE value of N. The range between the @1 and higher
values of HMSDCALE models the range between no pre-
publication review, that is no requirement of replication where
everything that shows any promise is published into the literature,
and a very stringent requirement of observing monotonic
improvement over many sequential observations. An
HMSDCALE of @1 is close to, but not quite literally publishing
everything because in a true publish-everything setting publication
would take place regardless of whether the patient’s health is
improving. I do not currently model ‘‘negative results’’–that is, a
well-powered study that shows no effect–nor publication of poor
outcomes–that is, replicable declining health status rather than
improving health status.
Modeling statistics were carried out by one-way ANOVA and
Tukey HSD post-hoc tests.
Supporting Information
Text S1 Stand Alone Simulation Common Lisp Code.
Found at: doi:10.1371/journal.pone.0010782.s001 (0.03 MB
TXT)
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